Divi's Laboratories Reports Strong FY26 Growth Amid Margin Stabilization

Divi's Laboratories reported a 14% increase in total income for the fiscal year ended March 31, 2026, reaching ₹11,067 crore. Profit After Tax (PAT) saw a 17.2% rise to ₹2,568 crore, up from ₹2,191 crore in FY25. The company also recorded a forex gain of ₹211 crore.

Reader Takeaway: Healthy revenue growth continues, but margins face pressure from market conditions.

What just happened

For the fiscal year 2026, Divi's Laboratories reported a total income of ₹11,067 crore, a 14% increase compared to ₹9,712 crore in the previous fiscal year. Profit Before Tax (PBT) rose by 16.2% to ₹3,388 crore, and Profit After Tax (PAT) grew by 17.2% to ₹2,568 crore. The company noted an exceptional item of ₹74 crore for Labour Code compliance. Margins have stabilized around 32%, a decrease from historical levels of 37-38%, attributed to generic pricing pressures and increased raw material costs.

Why this matters

The 14% revenue growth indicates continued demand for Divi's products and successful capacity utilization. However, the stabilization of margins at 32% is a key point for investors. While the company aims to return to historical margin levels, this is dependent on market conditions and product mix. Operational updates, including the ramp-up of Unit 3 and expansion in the peptide business, signal strategic focus on future growth drivers.

The backstory

Divi's Laboratories has historically maintained strong margins, often in the 37-38% range. The current dip to around 32% is a noticeable shift. The company navigated supply chain disruptions, including supplier force majeure declarations and geopolitical tensions in West Asia, without production stoppages. Significant capital expenditure of ₹1,544 crore was capitalized in FY26, indicating ongoing investment in future capacity.

What changes now

The company is actively working on optimizing its manufacturing footprint by transferring activities to Unit 3 for backward integration and enhancing its peptide business capabilities. Investors will be watching how effectively the newly capitalized assets translate into revenue and whether margins can recover towards historical levels.

Risks to watch

Key risks include persistent generic pricing pressure, rising raw material costs, and potential fluctuations in freight costs, which management expects to continue in the near term. The timeline for realizing returns from capital expenditure is also subject to external regulatory approvals, adding an element of uncertainty.

Peer comparison

While specific peer financial data for the same period is not detailed in the filing, the industry faces challenges like pricing erosion in generics and volatile raw material prices. Companies focusing on specialized products like peptides or with strong backward integration are often better positioned to weather these challenges.

Context metrics (time-bound)

• Total Income FY26: ₹11,067 crore (vs. ₹9,712 crore in FY25)
• PAT FY26: ₹2,568 crore (vs. ₹2,191 crore in FY25)
• Revenue Growth FY26: 14%
• PAT Growth FY26: 17.2%
• Margins stabilized around 32%
• Capex capitalized in FY26: ₹1,544 crore

What to track next

Investors should closely monitor the company's ability to improve its operating margins, the pace of revenue generation from new capex, and the performance of its peptide business. Any further updates on supply chain stability and raw material cost trends will also be crucial.